Lithium treatment alleviates impaired cognition in a mouse model of fragile X syndrome

M. K. King, Richard S Jope

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Fragile X syndrome (FXS) is caused by suppressed expression of fragile X mental retardation protein (FMRP), which results in intellectual disability accompanied by many variably manifested characteristics, such as hyperactivity, seizures and autistic-like behaviors. Treatment of mice that lack FMRP, Fmr1 knockout (KO) mice, with lithium has been reported to ameliorate locomotor hyperactivity, prevent hypersensitivity to audiogenic seizures, improve passive avoidance behavior and attenuate sociability deficits. To focus on the defining characteristic of FXS, which is cognitive impairment, we tested if lithium treatment ameliorated impairments in four cognitive tasks in Fmr1 KO mice, tested if the response to lithium differed in adolescent and adult mice and tested if therapeutic effects persisted after discontinuation of lithium administration. Fmr1 KO mice displayed impaired cognition in the novel object detection task, temporal ordering for objects task and coordinate and categorical spatial processing tasks. Chronic lithium treatment of adolescent (from 4 to 8weeks of age) and adult (from 8 to 12weeks of age) mice abolished cognitive impairments in all four cognitive tasks. Cognitive deficits returned after lithium treatment was discontinued for 4weeks. These results show that Fmr1 KO mice exhibit severe impairments in these cognitive tasks, that lithium is equally effective in normalizing cognition in these tasks whether it is administered to young or adult mice and that lithium administration must be continued for the cognitive improvements to be sustained. These findings provide further evidence that lithium administration may be beneficial for individuals with FXS. Chronic lithium treatment of adult or adolescent FX mice reverses impaired novel object detection performance.

Original languageEnglish
Pages (from-to)723-731
Number of pages9
JournalGenes, Brain and Behavior
Volume12
Issue number7
DOIs
StatePublished - Oct 1 2013

Fingerprint

Fragile X Syndrome
Lithium
Cognition
Knockout Mice
Fragile X Mental Retardation Protein
Therapeutics
Seizures
Avoidance Learning
Therapeutic Uses
Intellectual Disability
Young Adult
Hypersensitivity

Keywords

  • Cognition
  • Fragile X syndrome
  • Learning
  • Lithium
  • Novel object detection
  • Spatial processing

ASJC Scopus subject areas

  • Behavioral Neuroscience
  • Genetics
  • Neurology

Cite this

Lithium treatment alleviates impaired cognition in a mouse model of fragile X syndrome. / King, M. K.; Jope, Richard S.

In: Genes, Brain and Behavior, Vol. 12, No. 7, 01.10.2013, p. 723-731.

Research output: Contribution to journalArticle

@article{d4b52dd33d1c4f9c90d51bff72645b41,
title = "Lithium treatment alleviates impaired cognition in a mouse model of fragile X syndrome",
abstract = "Fragile X syndrome (FXS) is caused by suppressed expression of fragile X mental retardation protein (FMRP), which results in intellectual disability accompanied by many variably manifested characteristics, such as hyperactivity, seizures and autistic-like behaviors. Treatment of mice that lack FMRP, Fmr1 knockout (KO) mice, with lithium has been reported to ameliorate locomotor hyperactivity, prevent hypersensitivity to audiogenic seizures, improve passive avoidance behavior and attenuate sociability deficits. To focus on the defining characteristic of FXS, which is cognitive impairment, we tested if lithium treatment ameliorated impairments in four cognitive tasks in Fmr1 KO mice, tested if the response to lithium differed in adolescent and adult mice and tested if therapeutic effects persisted after discontinuation of lithium administration. Fmr1 KO mice displayed impaired cognition in the novel object detection task, temporal ordering for objects task and coordinate and categorical spatial processing tasks. Chronic lithium treatment of adolescent (from 4 to 8weeks of age) and adult (from 8 to 12weeks of age) mice abolished cognitive impairments in all four cognitive tasks. Cognitive deficits returned after lithium treatment was discontinued for 4weeks. These results show that Fmr1 KO mice exhibit severe impairments in these cognitive tasks, that lithium is equally effective in normalizing cognition in these tasks whether it is administered to young or adult mice and that lithium administration must be continued for the cognitive improvements to be sustained. These findings provide further evidence that lithium administration may be beneficial for individuals with FXS. Chronic lithium treatment of adult or adolescent FX mice reverses impaired novel object detection performance.",
keywords = "Cognition, Fragile X syndrome, Learning, Lithium, Novel object detection, Spatial processing",
author = "King, {M. K.} and Jope, {Richard S}",
year = "2013",
month = "10",
day = "1",
doi = "10.1111/gbb.12071",
language = "English",
volume = "12",
pages = "723--731",
journal = "Genes, Brain and Behavior",
issn = "1601-1848",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Lithium treatment alleviates impaired cognition in a mouse model of fragile X syndrome

AU - King, M. K.

AU - Jope, Richard S

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Fragile X syndrome (FXS) is caused by suppressed expression of fragile X mental retardation protein (FMRP), which results in intellectual disability accompanied by many variably manifested characteristics, such as hyperactivity, seizures and autistic-like behaviors. Treatment of mice that lack FMRP, Fmr1 knockout (KO) mice, with lithium has been reported to ameliorate locomotor hyperactivity, prevent hypersensitivity to audiogenic seizures, improve passive avoidance behavior and attenuate sociability deficits. To focus on the defining characteristic of FXS, which is cognitive impairment, we tested if lithium treatment ameliorated impairments in four cognitive tasks in Fmr1 KO mice, tested if the response to lithium differed in adolescent and adult mice and tested if therapeutic effects persisted after discontinuation of lithium administration. Fmr1 KO mice displayed impaired cognition in the novel object detection task, temporal ordering for objects task and coordinate and categorical spatial processing tasks. Chronic lithium treatment of adolescent (from 4 to 8weeks of age) and adult (from 8 to 12weeks of age) mice abolished cognitive impairments in all four cognitive tasks. Cognitive deficits returned after lithium treatment was discontinued for 4weeks. These results show that Fmr1 KO mice exhibit severe impairments in these cognitive tasks, that lithium is equally effective in normalizing cognition in these tasks whether it is administered to young or adult mice and that lithium administration must be continued for the cognitive improvements to be sustained. These findings provide further evidence that lithium administration may be beneficial for individuals with FXS. Chronic lithium treatment of adult or adolescent FX mice reverses impaired novel object detection performance.

AB - Fragile X syndrome (FXS) is caused by suppressed expression of fragile X mental retardation protein (FMRP), which results in intellectual disability accompanied by many variably manifested characteristics, such as hyperactivity, seizures and autistic-like behaviors. Treatment of mice that lack FMRP, Fmr1 knockout (KO) mice, with lithium has been reported to ameliorate locomotor hyperactivity, prevent hypersensitivity to audiogenic seizures, improve passive avoidance behavior and attenuate sociability deficits. To focus on the defining characteristic of FXS, which is cognitive impairment, we tested if lithium treatment ameliorated impairments in four cognitive tasks in Fmr1 KO mice, tested if the response to lithium differed in adolescent and adult mice and tested if therapeutic effects persisted after discontinuation of lithium administration. Fmr1 KO mice displayed impaired cognition in the novel object detection task, temporal ordering for objects task and coordinate and categorical spatial processing tasks. Chronic lithium treatment of adolescent (from 4 to 8weeks of age) and adult (from 8 to 12weeks of age) mice abolished cognitive impairments in all four cognitive tasks. Cognitive deficits returned after lithium treatment was discontinued for 4weeks. These results show that Fmr1 KO mice exhibit severe impairments in these cognitive tasks, that lithium is equally effective in normalizing cognition in these tasks whether it is administered to young or adult mice and that lithium administration must be continued for the cognitive improvements to be sustained. These findings provide further evidence that lithium administration may be beneficial for individuals with FXS. Chronic lithium treatment of adult or adolescent FX mice reverses impaired novel object detection performance.

KW - Cognition

KW - Fragile X syndrome

KW - Learning

KW - Lithium

KW - Novel object detection

KW - Spatial processing

UR - http://www.scopus.com/inward/record.url?scp=84884988657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884988657&partnerID=8YFLogxK

U2 - 10.1111/gbb.12071

DO - 10.1111/gbb.12071

M3 - Article

C2 - 23941202

AN - SCOPUS:84884988657

VL - 12

SP - 723

EP - 731

JO - Genes, Brain and Behavior

JF - Genes, Brain and Behavior

SN - 1601-1848

IS - 7

ER -